[ad_1]
The head of the Centers for Disease Control and Prevention (CDC) said on Tuesday that a COVID-19 vaccine would begin to be available in the United States “likely by the end of the second week of December.”
CDC Director Robert Redfield, appearing on Fox News’ “The Daily Briefing,” said a vaccine would first be distributed “in a hierarchical fashion,” with priority going to “nursing home residents and then to a combination of high risk providers of poor outcomes. “
On Monday, AstraZeneca and the University of Oxford said their co-created COVID-19 vaccine was found to be up to 90% effective and easier to distribute than another potential vaccine, which must be stored at lower temperatures to zero.
“These results show that we have an effective vaccine that will save many lives,” said Andrew Pollard, professor at the University of Oxford, who was the principal investigator of the drug trials. “Because the vaccine can be stored at refrigerator temperature, it can be distributed around the world using the normal immunization distribution system. And so our goal … to make sure we have a vaccine available everywhere, I think we’ve been successful in doing that.
Two other drugmakers in recent weeks have also announced successful testing of COVID-19 vaccines.
A new Moderna vaccine that was developed in conjunction with the Trump administration’s Operation Warp Speed is nearly 95 percent effective, according to the company.
“The analysis assessed 95 confirmed Covid-19 infections among the 30,000 trial participants,” CNBC reported earlier this month. Moderna, which developed its vaccine in collaboration with the National Institute of Allergies and Infectious Diseases, said 90 cases of Covid-19 were observed in the placebo group against 5 cases observed in the group that received its vaccine. in two doses. This resulted in an estimated vaccine efficacy of 94.5%. “
And pharmaceutical company Pfizer said on Nov. 9 that its developmental COVID-19 vaccine could be 90 percent effective in inoculating people with the disease. The efficacy rate was calculated by analyzing initial data from 94 trial participants in a study involving 43,538 subjects from around the world.
“Overall, if the Moderna and Pfizer vaccines are approved by the FDA, the United States could have up to 60 million doses of vaccine available by the end of the year,” Fox reported. “[T]The government could have access to more than a billion doses from the two vaccine manufacturers alone by 2021. “
But the Oxford-AstraZeneca vaccine is cheaper than the other two. “AstraZeneca, which has promised not to make a profit on the vaccine during the pandemic, has made deals with governments and international health organizations that estimate its cost at around $ 2.50 per dose. Pfizer’s vaccine costs about $ 20 a dose, while Moderna’s is $ 15 to $ 25, based on agreements companies have made to supply their vaccines to the US government, ”The Associated Press reported.
The Food and Drug Administration (FDA) has scheduled a December 10 meeting of its Advisory Committee on Vaccines and Related Biologics to discuss Pfizer’s request for Emergency Use Authorization (EUA) for its vaccine candidate. .
Related: Third Major COVID-19 Vaccine Up To 90% Effective, Trial Results Show
The Daily Wire is one of the fastest growing conservative media companies in the United States and a counter-cultural media for news, opinion and entertainment. Access The Daily Wire by becoming a member.
[ad_2]
Source link